Immunotherapy for Gastroesophageal Cancer.
Survival for patients with advanced oesophageal and stomach cancer is poor; together these cancers are responsible for more than a million deaths per year globally. As chemotherapy and targeted therapies such as trastuzumab and ramucirumab result in modest improvements in survival but not long-term cure for such patients, development of alternative treatment approaches is warranted. Novel immunotherapy drugs such as checkpoint inhibitors have been paradigm changing in melanoma, non-small cell lung cancer and urothelial cancers. In this review, we assess the early evidence for efficacy of immunotherapy in patients with gastroesophageal cancer in addition to considering biomarkers associated with response to these treatments. Early results of Anti- Programmed Cell Death Protein-1 (anti-PD-1), anti-PD-L1 and anti-Cytotoxic T-lymphocyte assosciated protein-4 (anti-CTLA4) trials are examined, and we conclude with a discussion on the future direction for immunotherapy for gastroesophageal cancer patients.
The Royal Marsden Hospital, NHS Foundation Trust, London SW3 6JJ, UK. Emily.goode@rmh.nhs.uk.
Emily F
EF
Goode
The Royal Marsden Hospital, NHS Foundation Trust, London SW3 6JJ, UK. Elizabeth.smyth@rmh.nhs.uk.
Elizabeth C
EC
Smyth
anti-PD-1; anti-PD-L1; checkpoint inhibitor; esophageal cancer; gastric cancer; immunotherapy; ipilimumab; nivolumab; pembrolizumab
Best Pract Res Clin Gastroenterol. 2006;20(4):633-49
16997150
Int J Cancer. 2015 Mar 1;136(5):E359-86
25220842
Clin Cancer Res. 2010 Mar 1;16(5):1662-72
20179239
Nat Genet. 2016 Jul;48(7):725-32
27240091
Int J Cancer. 2008 Nov 15;123(10):2362-9
18729190
Annu Rev Med. 2016;67:165-83
26332003
Cancer Res. 2010 Feb 15;70(4):1430-40
20124475
J Clin Oncol. 2012 May 1;30(13):1513-8
22412140
J Clin Oncol. 2006 Nov 1;24(31):4991-7
17075117
Int J Oncol. 2012 Oct;41(4):1297-304
22842485
N Engl J Med. 2008 Jan 3;358(1):36-46
18172173
Clin Cancer Res. 2002 Jun;8(6):1767-71
12060615
Ann Surg Oncol. 2009 Sep;16(9):2510-5
19565284
J Gastroenterol Hepatol. 2011 Mar;26(3):585-92
21332554
Gut. 2015 Nov;64(11):1721-31
25385008
Int J Cancer. 2012 Feb 1;130(3):584-92
21413013
Nature. 2014 Nov 27;515(7528):568-71
25428505
Hum Pathol. 2014 Feb;45(2):285-93
24331841
Science. 2014 May 9;344(6184):641-5
24812403
Sci Transl Med. 2014 Feb 19;6(224):224ra25
24553386
J Clin Oncol. 2015 May 20;33(15):1688-96
25800760
Gut. 2014 Feb;63(2):236-43
23580779
Br J Cancer. 2008 Nov 18;99(10):1704-11
18941457
Clin Cancer Res. 2002 Nov;8(11):3394-400
12429626
Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1188-94
18483341
Ther Adv Med Oncol. 2016 Mar;8(2):113-25
26929787
Lancet Oncol. 2016 Jun;17(6):682-3
27157490
Science. 1995 May 5;268(5211):738-40
7632227
Int J Cancer. 2012 Jul 15;131(2):505-11
21898388
Lancet Oncol. 2014 Oct;15(11):1224-35
25240821
Hum Pathol. 2008 Jun;39(6):925-32
18440592
J Immunol Methods. 2011 Nov 30;374(1-2):1-4
21986107
Mod Pathol. 2002 Jun;15(6):632-40
12065777
Br J Cancer. 2008 Jan 15;98(1):148-53
18087278
N Engl J Med. 2015 Jan 22;372(4):311-9
25482239
N Engl J Med. 2015 Nov 5;373(19):1803-13
26406148
Lancet Oncol. 2014 Jan;15(1):78-86
24332238
Clin Cancer Res. 2001 Aug;7(8):2277-84
11489802
J Immunother Cancer. 2013 Jul 29;1:12
24829749
Nature. 2014 Sep 11;513(7517):202-9
25079317
J Exp Med. 2009 Aug 3;206(8):1717-25
19581407
Br J Cancer. 2001 Sep 1;85(5):713-20
11531257
Cancer. 2010 Nov 15;116(22):5188-99
20665489
N Engl J Med. 2015 Jun 25;372(26):2521-32
25891173
Histopathology. 2011 Nov;59(5):822-31
22092393
Cancer. 2006 May 1;106(9):1908-16
16568451
Blood. 2016 Jun 16;127(24):2980-90
27118452
Cancer Immun. 2007 Apr 19;7:9
17441676
Lancet. 2014 Jan 4;383(9911):31-9
24094768
Lancet. 2015 Oct 10;386(10002):1457-64
26142048
Gastroenterology. 1995 Nov;109(5):1522-5
7557134
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20429-34
19915147
J Natl Compr Canc Netw. 2010 Apr;8(4):437-47
20410336
Lancet Oncol. 2016 Jun;17(6):717-26
27157491
Oncoimmunology. 2012 Nov 1;1(8):1239-1247
23243587
Am Soc Clin Oncol Educ Book. 2016;35:e493-503
27249758
Nat Rev Cancer. 2010 Jun;10(6):403-14
20495574
N Engl J Med. 2015 Jul 9;373(2):123-35
26028407
Surgery. 2006 Mar;139(3):347-56
16546499
Gut. 2016 Jan 22;:null
26801886
Mod Pathol. 2003 Jul;16(7):641-51
12861059
J Immunol. 2004 Feb 15;172(4):2324-31
14764701
N Engl J Med. 2015 Jul 2;373(1):23-34
26027431
N Engl J Med. 2015 Jun 25;372(26):2509-20
26028255
Vaccine. 2009 Nov 16;27(49):6854-61
19761832
BMC Cancer. 2015 Oct 17;15:727
26475790
J Transl Med. 2013 Oct 05;11:246
24093426
Lancet. 2010 Aug 28;376(9742):687-97
20728210
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16013-8
16247014
Korean J Pathol. 2013 Feb;47(1):28-35
23483099
Cancer Res. 2012 Mar 1;72(5):1081-91
22237626